Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 226,541,792 papers from all fields of science
Search
Sign In
Create Free Account
MD2 (cryptography)
Known as:
Message Digest Algorithm 2
The MD2 Message-Digest Algorithm is a cryptographic hash function developed by Ronald Rivest in 1989. The algorithm is optimized for 8-bit computers…
Expand
Wikipedia
(opens in a new tab)
Create Alert
Alert
Related topics
Related topics
35 relations
8-bit
Avalanche effect
BeRTOS
Birthday attack
Expand
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2017
2017
Distinct regulatory effects of myeloid cell and endothelial cell Nox2 on blood pressure
M. Schnelle
,
Juqian Zhang
,
+11 authors
P. Eaton
2017
Corpus ID: 54811181
BACKGROUND: Hypertension caused by increased renin-angiotensin system activation is associated with elevated reactive oxygen…
Expand
2015
2015
Achieving Business Practicability of Model-Driven Cross-Platform Apps
Tim A. Majchrzak
,
J. Ernsting
,
H. Kuchen
Open Journal of Information Systems
2015
Corpus ID: 18340771
Due to the incompatibility of mobile device platforms such as Android and iOS, apps have to be developed separately for each…
Expand
2015
2015
Vancomycin-Resistant Enterococcal iters Diminish Among Patients With Recurrent Clostridium difficile Infection After Administration of SER-109, A Novel Microbiome Agent
M. Lombardo
,
M. Vulić
,
+6 authors
E. Hohmann
2015
Corpus ID: 74357753
Background Mary-Jane Lombardo, PhD1, Marin Vulic, PhD1, Toshi Ohsumi, PhD1, David Cook, PhD1, Matthew Henn, PhD1, Colleen Kraft…
Expand
2015
2015
Ublituximab + TGR-1202 Demonstrates Activity and a Favorable Safety Profile in Relapsed/Refractory B-Cell NHL and High-Risk CLL: Phase I Results
M. Lunning
,
J. Vose
,
+16 authors
S. O'brien
2015
Corpus ID: 57310257
Introduction: Ublituximab (UTX) is a novel anti-CD20 mAb that has been glycoengineered for enhanced ADCC. TGR-1202 is a novel…
Expand
Review
2015
Review
2015
Ibrutinib Versus Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Results From the Randomized Phase III RESONATE™ (PCYC-1112) Trial
Jennifer R. Brown
,
J. Byrd
,
+17 authors
P. Hillmen
2015
Corpus ID: 74295456
2014
2014
Risk on Dynamic Behavior of Farmers in the Export Market: A Case from the Pineapple Industry in Ghana
A. Suzuki
2014
Corpus ID: 150530125
While the role of risks in technology adoption is a classical topic, its effects beyond adoption have not been examined well…
Expand
2013
2013
Encephalitis and antibodies to DPPX , a subunit of Kv 4 . 2 potassium channels
A. Boronat
,
J. Gelfand
,
+9 authors
J. Dalmau
2013
Corpus ID: 16205686
Anna Boronat, BS1, Jeffrey M. Gelfand, MD2, Nuria Gresa-Arribas, PhD1, Hyo-Young Jeong, PhD3, Michael Walsh, MD4, Kirk Roberts…
Expand
2010
2010
Identification of Candida species from Human Immunodeficiency Virus-infected Patients in Ethiopia by Combination of CHROMagar, Tobacco agar and PCR of Amplified Internally Transcribed rRNA Spacer…
H. Isogai
,
A. Mulu
,
+5 authors
E. Isogai
2010
Corpus ID: 55707621
The purpose of this study was to determine phenotypic and genotypic identification of Candida species from HIV infected patients…
Expand
2006
2006
MD2 Method: The Didactic Materials Creation from a Model Based Perspective
C. Padrón
,
P. Díaz
,
I. Aedo
European Conference on Technology Enhanced…
2006
Corpus ID: 28207052
The creation of didactic materials is a complex task that needs an effective support for all practitioners involved in such…
Expand
2005
2005
Integrating Ontologies into the Collaborative Authoring of Learning Objects
J. Dodero
,
P. Díaz
,
I. Aedo
,
Antonio Sarasa Cabezuelo
Journal of universal computer science (Online)
2005
Corpus ID: 2796816
Authoring learning material is a multi-disciplinary undertaking where different people can play their role. Any support that can…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE